TBE vaccination breakthrough cases—Does age matter?

Heinz J. Schmitt, Gerhard Dobler, Dace Zavadska, Zane Freimane, Dimitrios Fousteris, Wilhelm Erber, Luis Jodar, Andreas Palmborg (Coresponding Author)

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
7 Downloads (Pure)


Tick-borne encephalitis (TBE) vaccines are highly effective in preventing TBE and vaccine failures (VF) are rare events. In this study, we compared the age distribution of TBE cases and TBE VF in three endemic countries: Sweden, Southern Germany, and Latvia. While the age distribution of TBE cases was similar for those <50 years versus those ≥50 years in all three countries, in Sweden, a higher proportion of VF cases was ≥50 years, whereas most VF cases in Latvia were <50 years of age and more evenly distributed between those <50 years versus those ≥50 in Southern Germany. Here, theoretical explanations were provided, including differences in diagnostic practices, vaccine uptake between age groups, behavioral patterns and underlying medical conditions, as to why VF were generally older in Sweden than the other countries. There is no scientific rationale to give an extra priming dose of TBE vaccine to subjects ≥50 years of age.

Original languageEnglish
Article number932
Issue number8
Publication statusPublished - 21 Aug 2021


  • Older adults
  • Sweden
  • Tick-borne encephalitis
  • Vaccination failure
  • Vaccine failure

Field of Science*

  • 3.2 Clinical medicine
  • 3.3 Health sciences

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database


Dive into the research topics of 'TBE vaccination breakthrough cases—Does age matter?'. Together they form a unique fingerprint.

Cite this